Overview

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Status:
RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Phase:
PHASE3
Details
Lead Sponsor:
Celltrion